Research Tree Research Tree Logo

  • Try our Investor Tool
  • Login
  • Sign Up
  • Providers
  • Companies

Research Tree Logo

  • Login
  • Sign Up
  • Features
  • Pricing
  • RNS/News
  • Contact
  • Try our Investor Tool
  • Login
  • Sign Up
  • Providers
  • Companies
  • Features
  • Pricing
  • RNS/News
  • Short Interest Tracker
  • Blogs
    • Academy
    • Insights
    • News
    • Research Tree
    • The Naked Fund Manager
  • Ideas & Picks
    • Ideas Hub
    • Stock Pick League
    • Themes & Screens Hub
  • Explore Content
    • Regions
      UK Rest of EMEA N America APAC LatAm
    • Sectors
      Automobile Industry Banks Building & Construction Chemicals Discretionary Personal Goods Discretionary Retail Energy Financial Services Food & Drink Food Production Health Household Goods & DIY Industrial Equipment, Goods & Services Insurance & Reinsurance Leisure, Tourism & Travel Media Other Real Estate Resources Staple Retail Technology Telecoms Trusts, ETFs & Funds Utilities
    • Small / Large Cap
      UK100 UK250 UK Smallcap UK Other Main Markets Other
    • Private/EIS
      EIS Single Company EIS/SEIS Funds IHT Products SEIS Single Company VCT Funds
  • Providers
    • Free/Commissioned
      Align Research BRR Media Capital Access Research Edison Equity Development Fidante Partners Five Minute Pitch TV goetzpartners securities Limited Hardman & Co Independent Investment Research Kepler | Trust Intelligence piworld.co.uk Proactive Progressive Equity Research QuotedData Radnor Capital Partners Research Tree Trinity Delta
    • High Net Worth Offering
      Allenby Capital AlphaValue Arden Partners Cenkos Securities Dowgate Capital finnCap First Berlin GMP FirstEnergy Hybridan Liberum Louis Capital Marten & Co Medley Global Advisors N+1 Singer Northland Capital Partners SP Angel Stanford Capital Partners Stockdale Securities Tamesis Partners The Life Sciences Division VSA Capital WHIreland Whitman Howard Zeus Capital
    • Institutional Offering
      Align Research Allenby Capital AlphaValue Arden Partners BRR Media Bryan, Garnier & Co Capital Access Research Cenkos Securities Dowgate Capital Edison Equity Development Fidante Partners finnCap First Berlin Five Minute Pitch TV GMP FirstEnergy goetzpartners securities Limited Hardman & Co Hybridan Independent Investment Research Kepler | Absolute Hedge Kepler | Trust Intelligence Liberum Longspur Research N+1 Singer Northland Capital Partners piworld.co.uk Proactive Progressive Equity Research QuotedData Radnor Capital Partners Research Tree Shore Capital SP Angel Stanford Capital Partners Stifel Stockdale Securities Tamesis Partners The Life Sciences Division Trinity Delta VSA Capital WHIreland Whitman Howard Zeus Capital
    • Video/Audio Interviews
      BRR Media Edison Equity Development Five Minute Pitch TV piworld.co.uk Proactive Research Tree
  • Contact
Companies >
New Zealand >
Pharmaceuticals >
AFT Pharmaceuticals >
Research >
Strong FY18 results

  • 30 May 2018

Strong FY18 results


AFT Pharmaceuticals | AFT | 0 0 0.0%


  • Edison
    • Maxim Jacobs

    • 6 pages

Pharmaceuticals image



 
Pharmaceuticals image



AFT Pharmaceuticals recently reported its FY18 results. Operating revenue grew 15.7% compared to FY17, approximately double the 8.1% growth seen the year before. The Australian market, which now represents over 61% of revenues at N$49.2m, was leading the way with 32.7% growth, thanks to patients switching from codeine-containing products. Revenues in New Zealand fell by 7% from NZ$29.2m to NZ$27.1m due to the company no longer being the sole supplier of Metoprolol. Maxigesic continues to do well internationally and is now launched in 10 countries.


Revenue in Australia was up 32.7% in FY18 compared to FY17, thanks in large part to Maxigesic sales increasing by 65%. Growth is expected to continue to be robust as patients switch from codeine-containing products (which are no longer available over the counter after 1 February 2018 due to re-scheduling) to Maxigesic.


Maxigesic is currently sold and launched in 10 countries and distribution agreements are in place in a total of 125. New launches were negatively affected by slower than expected registrations in the EU, but the company believes that regulatory delays are behind it, with launches in countries such as Spain, Portugal, France, Ireland and the Nordics expected by the end of CY18.


In January, the New Zealand Medicines Classification Committee announced a recommendation that all codeine combination medicines be upscheduled from over-the-counter to prescription-only status from 2020. This should boost Maxigesic sales in AFT’s home market considerably once it takes effect.


We are increasing our valuation to NZ$478m or NZ$4.91 per share from NZ$460m or NZ$4.73 per share, mainly due to increased expectations for Australian revenues due to higher Maxigesic sales and rolling forward our NPV. This was partly mitigated by slight reductions in expectations for New Zealand and Rest of World (RoW), and a higher net debt balance. We continue to expect that AFT will achieve EBITDA break-even in FY19.


Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here
See all the research we have on this company.

More Content

More Content

AFT Pharmaceuticals - A strong start to FY20

Companies: AFT Pharmaceuticals

Edison

A diversified, geographically expanding company

Companies: AFT Pharmaceuticals

Edison

AFT Pharmaceuticals - A licensing deal for Pascomer

Companies: AFT Pharmaceuticals

Edison

Investing to accelerate long-term growth

Companies: AFT Pharmaceuticals

Edison

AFT Pharmaceuticals - Operating profitability achieved

Companies: AFT Pharmaceuticals

Edison

Useful Links

  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub

Account

  • Login
  • Free Trial - Join Now
  • Contact
Follow us on Linkedin Follow us on Twitter

Share:

Heap | Mobile and Web Analytics

Copyright © 2019 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Tools licensed and contents implemented and optimized by Digital Look Ltd.

DigitalLook |Web Financial Group

©1999-2013 – Digital Look Ltd. A Web Financial Group Company All rights reserved. Legal notice.

Top
  • Home
  • Features
  • Pricing
  • RNS/News
  • Short Interest Tracker
  • Blogs
    • Academy
    • Insights
    • News
    • Research Tree
    • The Naked Fund Manager
  • Ideas & Picks
    • Ideas Hub
    • Stock Pick League
    • Themes & Screens Hub
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Leisure, Tourism & Travel
      • Media
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Trusts, ETFs & Funds
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Align Research
      • BRR Media
      • Capital Access Research
      • Edison
      • Equity Development
      • Fidante Partners
      • Five Minute Pitch TV
      • goetzpartners securities Limited
      • Hardman & Co
      • Independent Investment Research
      • Kepler | Trust Intelligence
      • piworld.co.uk
      • Proactive
      • Progressive Equity Research
      • QuotedData
      • Radnor Capital Partners
      • Research Tree
      • Trinity Delta
    • High Net Worth Offering
      • Allenby Capital
      • AlphaValue
      • Arden Partners
      • Cenkos Securities
      • Dowgate Capital
      • finnCap
      • First Berlin
      • GMP FirstEnergy
      • Hybridan
      • Liberum
      • Louis Capital
      • Marten & Co
      • Medley Global Advisors
      • N+1 Singer
      • Northland Capital Partners
      • SP Angel
      • Stanford Capital Partners
      • Stockdale Securities
      • Tamesis Partners
      • The Life Sciences Division
      • VSA Capital
      • WHIreland
      • Whitman Howard
      • Zeus Capital
    • Institutional Offering
      • Align Research
      • Allenby Capital
      • AlphaValue
      • Arden Partners
      • BRR Media
      • Bryan, Garnier & Co
      • Capital Access Research
      • Cenkos Securities
      • Dowgate Capital
      • Edison
      • Equity Development
      • Fidante Partners
      • finnCap
      • First Berlin
      • Five Minute Pitch TV
      • GMP FirstEnergy
      • goetzpartners securities Limited
      • Hardman & Co
      • Hybridan
      • Independent Investment Research
      • Kepler | Absolute Hedge
      • Kepler | Trust Intelligence
      • Liberum
      • Longspur Research
      • N+1 Singer
      • Northland Capital Partners
      • piworld.co.uk
      • Proactive
      • Progressive Equity Research
      • QuotedData
      • Radnor Capital Partners
      • Research Tree
      • Shore Capital
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • Stockdale Securities
      • Tamesis Partners
      • The Life Sciences Division
      • Trinity Delta
      • VSA Capital
      • WHIreland
      • Whitman Howard
      • Zeus Capital
    • Video/Audio Interviews
      • BRR Media
      • Edison
      • Equity Development
      • Five Minute Pitch TV
      • piworld.co.uk
      • Proactive
      • Research Tree
  • Contact
  • Sign Up
  • Sign In